Back to Journals » Breast Cancer: Targets and Therapy » Call For Papers
Breast Cancer: Targets and Therapy
The following Article Collections/ Thematic Series are currently open for submissions:
Targeting Triple-Negative Breast Cancers: Modern Advancements and Future Directions
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Targeting Triple-Negative Breast Cancers: Modern Advancements and Future Directions" in Breast Cancer: Targets and Therapy.
Triple negative breast cancer has historically been treated indiscriminately with chemotherapy based on the lack of known actionable alterations. The evolution of gene expression profiling, a greater understanding of the immune micro-environment, targeting of DNA damage repair pathways, and novel drug delivery methods have led to unprecedented advances in the management of triple negative breast cancer.
Despite these advances, the prognosis for patients with advanced triple negative breast cancer remains limited, highlighting an urgent unmet need. Moreover, it is imperative to identify patients at high risk of relapse and to understand mechanisms of sensitivity and resistance to modern therapeutic approaches.
This Article Collection seeks to summarize the current treatment paradigms, novel treatment combinations and ongoing efforts seeking to overcome drug resistance in the advanced setting. Topics of interest include:
- Novel treatment combinations
- Immunotherapy, comprising treatment combinations
- Antibody drug conjugates, novel targets and payloads
- Exploitation of the DNA damage repair pathways
- Treatment sequencing in a modern era
- Molecular residual disease and treatment resistance monitoring
The deadline for submissions is 29 September 2023.
Please submit your manuscript on our website, quoting the promo code OFSGO to indicate that your submission is for consideration in this Article Collection.
Nathalie Levasseur, British Columbia Cancer Agency & University of British Columbia
Invasive Lobular Carcinoma: A Distinctive Entity
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Invasive Lobular Carcinoma: A Distinctive Entity" in Breast Cancer: Targets and Therapy.
The clinical management of breast cancer is primarily structured around molecular subtype (i.e. hormone receptor positive, HER2 positive, or triple negative), which guides the clinical course; with lesser emphasis placed on other classifiers notably histology type. Invasive breast carcinomas are largely ductal with regard to histology and thus standards of care and clinical trials are heavily represented by patients with invasive ductal carcinoma (IDC). Patients with invasive lobular carcinoma (ILC) comprise roughly 15% of all cases, which given the high frequency of breast cancer translates to a large population that are categorically underrepresented in this process. Unique features and clinical behaviors associated with ILC are well appreciated in practice and in the literature, yet standard of care guidelines are not reflective of this. The goal of this Article Collection is to highlight the nuances in the management of ILC and the advances made to better understand the implications of these distinctive features.
Topics of interest include but are not limited to:
- ILC response to systemic therapies (cytotoxic, targeted, and endocrine directed therapies)
- Transcriptomics of ILC
- ILC and microenvironment
- Optimal surveillance imaging in ILC
The deadline for submissions is 15 October 2023. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code VMSTP to indicate that your submission is for consideration in this Article Collection.
Azadeh Nasrazadani, University of Texas MD Anderson Cancer Center
Targeting Stem Cells for Breast Cancer Therapy
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Targeting Stem Cells for Breast Cancer Therapy" in Breast Cancer: Targets and Therapy.
In the past four decades, an improved survival rate in breast cancer patients has been witnessed, largely due to early diagnosis and the advent of new targeted therapies. However, the increase in cancer-specific survival seems to have reached a plateau in 2005. Tumor recurrence and relapse are the major clinical challenges in treatment of breast cancer patients. Since breast cancer stem cells (CSCs) were first identified in 2003, they have been considered promising therapeutic targets for cancer therapy. CSCs are a small population of cancer cells which are thought to be responsible for tumor initiation, progression, recurrence, and more importantly drug resistance.
Over the past two decades, much progress has been made to understand how CSCs are regulated by intrinsic factors such as aberrantly activated oncogenic, epithelial-mesenchymal transition, anti-apoptotic, metabolic detoxification pathways as well as extracellular factors such as vascular niches, hypoxia, stromal cells, extracellular matrix, and exosomes. Based on these developments, both chemotherapeutic drugs and immunotherapeutic strategies have been developed to specifically target BCSCs, and some of these factors are already undergoing clinical trials in recent years.
This Article Collection aims to collect the most recent progress made by multidisciplinary researchers in tackling the key challenges in development of breast CSCs-targeted therapies which include, but are not limited to, differentiation therapy, nano-drug delivery and targeted therapy, immunotherapy and epigenetic modification and blockades of microenvironmental cues.
Keywords: breast cancer stem cells, tumor microenvironments, immunotherapy, chemotherapy, drug resistance, epithelial-mesenchymal transition
• Original research (main)
• Expert opinion
• Case series
The deadline for submissions is 31 October 2023. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code GQFVO to indicate that your submission is for consideration in this Article Collection.
Hexin Chen, University of South Carolina
Dr. Hexin Chen is a Professor of Biology at the University of South Carolina. He received his Ph.D. in molecular biology at the University of Nebraska-Lincoln and completed his postdoctoral training in breast cancer biology at Johns Hopkins University School of Medicine. His current research focuses on studying breast cancer stem cells (CSCs). His lab is especially interested in understanding how CSCs communicate with tumor microenvironment and how these interactions impact on tumor growth and development of therapeutic resistance.
Call For Papers
To see where Breast Cancer: Targets and Therapy is indexed online view the Journal Metrics.
What is the advantage to you of publishing in Breast Cancer: Targets and Therapy?
- It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove Medical Press website.
- Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
- The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Breast Cancer: Targets and Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
- Many authors have found that our peer reviewers’ comments substantially add to their final papers.
To recover our editorial and production costs, and continue to provide our content at no cost to readers, we charge authors or their institution an article publishing charge.
Breast Cancer: Targets and Therapy is indexed on PubMed Central (title abbreviation Breast Cancer (Auckl)). All published papers in this journal are submitted to PubMed for indexing straight away
Become a Favored Author and receive real benefits
If you haven't already joined the Dove Medical Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal coordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page.
Professor Pranela Rameshwar
Breast Cancer: Targets and Therapy